ReviewDrugs2018
Danoprevir: First Global Approval.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.Antimicrobial agents and chemotherapy · 2021Trial
- Unraveling the therapeutic landscape of approved non-peptide macrocycles.Acta pharmaceutica Sinica. B · 2025Review
- Oxysulfonylation of Alkynes with Sodium Sulfinates to Access β-Keto Sulfones Catalyzed by BFMolecules (Basel, Switzerland) · 2024Article
- Photoredox-catalyzed sulfonylation of diaryliodonium salts with DABSO and silyl enolates involving the insertion of SORSC advances · 2024Article
- Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China.BMC gastroenterology · 2024Article
- Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Viral proteases as therapeutic targets.Molecular aspects of medicine · 2022Review
- Current trends in diagnosis and treatment strategies of COVID-19 infection.Environmental science and pollution research international · 2021Review
- Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.Future microbiology · 2020Article
- Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.SLAS discovery : advancing life sciences R & D · 2020Article
- Pharmacological treatments of COVID-19.Pharmacological reports : PR · 2020Review
- SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment.Biosafety and health · 2020Review
- COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus.European journal of medicinal chemistry · 2020Review
- A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).Complementary therapies in clinical practice · 2020Review
- Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application.Medicina (Kaunas, Lithuania) · 2020Review
- Clinical trials on drug repositioning for COVID-19 treatment.Revista panamericana de salud publica = Pan American journal of public health · 2020Article
- Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.Drug design, development and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascletis has developed danoprevir (Ganovo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.